aflibercept
Trade name: zaltrap
Recombinant proteinapproved
Approved
Nov 18, 2011
Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals. — Wikipedia
Clinical trial activity
419 trials · 292 clinical orgs · 7 marketing orgs
Phase 1
65
Phase 2
242
Phase 3
114
Phase 4
100
Earliest trial started Nov 1, 2001 (NCT00036946)
Timeline
2000s
2010s
- Nov 18, 2011
Earliest FDA Approval
- Nov 18, 2011
Regeneron — NDA Secondary Org
- Aug 3, 2012
Sanofi-Aventis — First NDA Organization
- Aug 3, 2012
Regeneron — Marketing Organization
- Aug 3, 2012
Sanofi-Aventis — Marketing Organization
- Aug 3, 2012
Sanofi-Aventis — NDA Organization
2020s
- May 20, 2024
Biocon Limited — Marketing Organization
- May 20, 2024
Samsung — Marketing Organization
- Aug 9, 2024
Sandoz — Marketing Organization
- Aug 23, 2024
Amgen — Marketing Organization
- Oct 2, 2025
Celltrion — Marketing Organization
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Ascites · Phase 2/Phase 3
- Astrocytoma · Phase 2
- Back Injuries · Phase 4
- Biliary Tract Neoplasms · Phase 1
- Body Fluids · Phase 4
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoid Tumor · Phase 2
- Carcinoma · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 2
- Cataract · Phase 4
- Central Serous Chorioretinopathy · Phase 4
- Choroidal Neovascularization · Phase 3
- Colonic Neoplasms · Phase 2
- Corneal Neovascularization · Phase 1/Phase 2
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 1 · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 2/Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Edema · Phase 2
- Endometrial Neoplasms · Phase 2
- Endothelium · Phase 4
- Esophageal Neoplasms · Phase 2
- Eye Diseases · Phase 3
- Fallopian Tube Neoplasms · Phase 2
- General Surgery · Early Phase 1
- Glaucoma · Phase 3
- Glaucoma, Neovascular · Phase 3
- Glioblastoma · Phase 2
- Glioma · Phase 1
- Gliosarcoma · Phase 2
- Graves Ophthalmopathy · Phase 2
- Hemorrhage · Phase 3
- Inflammation · Phase 2
- Leiomyosarcoma · Phase 2
- Leukemia · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Livedoid Vasculopathy · Phase 4
- Liver Neoplasms · Phase 1
- Lung Diseases · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Macula Lutea · Phase 4
- Macular Degeneration · Phase 4
- Melanoma · Phase 3
- Multiple Endocrine Neoplasia Type 1 · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Myopia, Degenerative · Phase 3
- Neoplasm Metastasis · Phase 3
- Neovascularization, Pathologic · Phase 4
- Oligodendroglioma · Phase 2
- Optic Nerve · Early Phase 1
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 2/Phase 3
- Pain · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 3
- Polypoidal Choroidal Vasculopathy · Phase 4
- Prostatic Neoplasms · Phase 3
- Pseudoxanthoma Elasticum · Phase 2
- Pterygium · Phase 2
- Rectal Neoplasms · Phase 2
- Retinal Degeneration · Phase 3
- Retinal Detachment · Phase 4
- Retinal Diseases · Phase 4
- Retinal Neovascularization · Phase 2
- Retinal Vein Occlusion · Phase 4
- Retinitis Pigmentosa · Phase 2
- Retinopathy of Prematurity · Phase 3
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Tomography, Optical Coherence · Phase 4
- Urethral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
- Vascular Diseases · Phase 4
- Vision, Ocular · Phase 1/Phase 2
- Vitreoretinopathy, Proliferative · Phase 2
- Vitreous Body · Phase 4
- Vitreous Hemorrhage · Phase 2/Phase 3
Mechanism of action
- Placenta growth factorINHIBITOR
PGF inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Approval history
- approvedNov 18, 2011
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaAflibercept ↗
- NCATS15C2VL427D ↗
- ChEMBLCHEMBL1742982 ↗
Also known as
- afilbercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- aflibercept
- alfilbercept
- ave0005
- ave0005
- ave0005
- ave 0005
- ave-0005
- ave005
- ave 005
- ave-005
- eylea
- eylea
- eylea
- eylea
- nt-503-3
- vascular endothelial growth factor trap-eye
- vegf trap
- vegf trap
- vegf trap
- vegf trap
- vegf-trap
- vegf trap-eye
- vegf trap-eye
- vegf trap - regeneron
- zaltrap
- zaltrap
- zaltrap
- zaltrap
- ziv-aflibercept
- ziv-aflibercept
- ziv-aflibercept
- ziv-aflibercept
- ziv-aflibercept
- ziv-aflibercept
- ziv-aflibercept
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07301775 | Phase 4 | Jan 1, 2026 | Sahiwal medical college sahiwal, University of Health Sciences Lahore |
| NCT06879301 | Early Phase 1 (Phase 1) | Oct 19, 2025 | Tanta University |
| NCT07205887 | Phase 2 | Sep 12, 2025 | EyeBiotech Ltd. |
| NCT07118670 | Phase 4 | Aug 31, 2025 | Greater Houston Retina Research |
| NCT07064759 | Phase 3 | Jul 22, 2025 | 4D Molecular Therapeutics |
| NCT06942520 | Phase 2 | Mar 18, 2025 | Regenxbio Inc., Sierra Eye Associates |
| NCT06929507 | N/A | Mar 10, 2025 | University of Alexandroupolis |
| NCT06864988 | Phase 3 | Mar 3, 2025 | 4D Molecular Therapeutics |
| NCT06856577 | Phase 3 | Feb 28, 2025 | Adverum Biotechnologies, Inc. |
| NCT06850571 | Phase 4 | Feb 20, 2025 | Al-Mustansiriyah University, Baghdad Medical City |
| NCT06839339 | Phase 2 | Feb 18, 2025 | Government of China |
| NCT06683742 | Phase 3 | Dec 31, 2024 | Eyepoint Pharmaceuticals |
| NCT06662994 | Phase 4 | Nov 15, 2024 | Regeneron, Retina Consultants of Orange County |
| NCT06610747 | N/A | Oct 31, 2024 | The Second People's Hospital of Foshan |
| NCT06668064 | Phase 3 | Oct 22, 2024 | Eyepoint Pharmaceuticals |
| NCT06683950 | Phase 4 | Oct 21, 2024 | Kim's Eye Hospital, Seoul, South Korea |
| NCT06470373 | Phase 3 | Sep 30, 2024 | Rophibio, Inc. |
| NCT06817343 | Phase 1 | Sep 10, 2024 | Exegenesis Bio |
| NCT06591598 | Phase 4 | Sep 2, 2024 | Bayer, Regeneron |
| NCT06556368 | Phase 3 | Aug 23, 2024 | Kodiak Sciences Inc |
Showing 20 of 419 trials
Page 1 / 21
Organizations
Research & Development (292)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 112 | 29 | 5 | 2001 |
| Bayer | For profit | 51 | 24 | 5 | 2005 |
| Sanofi | For profit | 40 | 22 | 3 | 2006 |
| National Cancer Institute (NCI) | Government | 27 | 20 | 3 | 2001 |
| Novartis | For profit | 18 | 16 | 2 | 2013 |
| Roche | For profit | 8 | 7 | 2 | 2018 |
| University of Toronto | Academic/Hospital | 8 | 5 | 2 | 2006 |
| Greater Houston Retina Research | Academic/Hospital | 7 | 6 | 2 | 2012 |
| Kodiak Sciences Inc | For profit | 6 | 6 | 2 | 2019 |
| The Cleveland Clinic | Academic/Hospital | 6 | 5 | 2 | 2012 |
| California Retina Consultants | Academic/Hospital | 5 | 3 | 3 | 2012 |
| Clearside Biomedical, Inc. | For profit | 5 | 5 | 2 | 2015 |
| Cornell University | Academic/Hospital | 5 | 0 | 2 | 2001 |
| Genentech | For profit | 5 | 1 | 2 | 2012 |
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 5 | 5 | 3 | 2020 |
| Iveric Bio | For profit | 5 | 4 | 3 | 2014 |
| Jaeb Center for Health Research | Academic/Hospital | 5 | 5 | 1 | 2012 |
| Kim's Eye Hospital, Seoul, South Korea | Academic/Hospital | 5 | 4 | 1 | 2014 |
| National Eye Institute (NEI) | Government | 5 | 0 | 1 | 2012 |
| Seoul National University | Academic/Hospital | 5 | 3 | 3 | 2014 |
292 organizations
Page 1 / 15
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amgen | For profit | MKTG | Aug 23, 2024 |
| Biocon Limited | For profit | MKTG | May 20, 2024 |
| Celltrion | For profit | MKTG | Oct 2, 2025 |
| Regeneron | For profit | MKTG | Aug 3, 2012 |
| Regeneron | For profit | IND | — |
| Regeneron | For profit | NDA2 | Nov 18, 2011 |
| Samsung | For profit | MKTG | May 20, 2024 |
| Sandoz | For profit | MKTG | Aug 9, 2024 |
| Sanofi-Aventis | For profit | MKTG | Aug 3, 2012 |
| Sanofi-Aventis | For profit | NDA | Aug 3, 2012 |